Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company focused on developing genetic medicines for rare neurological diseases, has announced the approval of non-qualified stock options as part of its new compensation plan. These options, known as Inducement Grants, were issued to four new employees as of June 5, 2025, under the company's 2025 Inducement Plan. The grants, aligned with Nasdaq Listing Rule 5635(c)(4), allow the purchase of a total of 39,345 shares of Neurogene's common stock at the closing price on the grant date. Vesting of these options occurs over four years, with an initial 25 percent vesting after the first year and the remainder in equal portions every three months, contingent upon ongoing employment with the company.